Chromatin remodeling may play a role in the neurobiology of schizophrenia and the process, therefore, may be considered as a therapeutic target. The SMARCA2 gene encodes BRM in the SWI/SNF chromatin-remodeling complex, and associations of single nucleotide polymorphisms (SNPs) to schizophrenia were found in two linkage disequilibrium blocks in the SMARCA2 gene after screening of 11 883 SNPs (rs2296212; overall allelic P 5 5.8 3 10
INTRODUCTION
Schizophrenia is a chronic, severe and disabling brain disorder that affects approximately 1% of the world's population. A large body of data consistently supports the involvement of complex genetic components causally linked to schizophrenia. Association studies including genome-wide scans have identified many risk alleles that have small effects (1 -5) . In addition to genetic studies, altered expression of many genes and proteins in schizophrenic brains has been documented (6) and epigenetic regulation in schizophrenia has also been studied (7) . Among epigenetic mechanisms, the role of chromatin modification in psychiatric disorders and related fields has been reported for epilepsy (8) , drug addiction (9,10), depression (11) , autism (12) , fear (13) , learning and memory (13, 14) , social cognition (15) and stress-related behaviors (16, 17) . Histone modifications may contribute to the pathogenesis of prefrontal dysfunction in schizophrenia (18) .
The SMARCA2 gene encodes BRM, one of the earliest described chromatin remodeling multiprotein complexes in the yeast SWI/SNF complex (19 -23) , and highly conserved among eukaryotes (24) . The SWI/SNF molecules are mutually exclusive within the complexes and harbor ATPase activity (25 -27) . This complex functions by destabilizing the interactions between DNA and histones in the nucleosome in an ATP-dependent reaction (28, 29) . Mammalian SWI/SNF complexes are present in biochemically diverse forms, indicating that they may have specialized nuclear functions (30) . ATPdependent remodeling complexes involved in chromatin opening or compaction are important in the regulation of transcriptional processes associated with development, cellular differentiation and oncogenesis (22, (31) (32) (33) (34) (35) .
BRM interacts with several transcription factors and other DNA-binding proteins and is involved in chromatin structural modification in the epigenetic regulation of gene expression (36) . SMARCA2 expression is induced to a high level during differentiation to neurons and astrocytes, suggesting an important role in neural cell differentiations (37) . Because BRM potentially influences expression of many genes, it is hypothesized that functional changes to SMARCA2/BRM may contribute to gene expression changes reported to occur in schizophrenia.
RESULTS
SNPs in two linkage disequilibrium blocks within the SMARCA2 gene were associated with schizophrenia in the Japanese population Initially, in 100 Japanese schizophrenic patients, 11 883 SNPs were screened for association with schizophrenia. These SNPs exist on the Illumina Human-1 BeadChip and are also deposited in a Japanese SNP (JSNP) database of 1480 Japanese control chromosomes (http://snp.ims.u-tokyo.ac.jp/ index.html). The potential impact of population structure on this association study was evaluated by using the genomewide x 2 inflation factor, l, as a genomic control (38, 39) . The estimated value of l was 1.05, by which genome-wide association P-values were corrected. After correction for multiple testing of these 11 883 SNPs, no significant association was found between them and schizophrenia (Supplementary Material, Table S1 ).
In the replication 1 cohort, comprised of 576 Japanese schizophrenic patients and 576 Japanese control subjects, an attempt was made to replicate the association of the top 5 SNPs, as ranked by the association P-values, with schizophrenia. A potential association was found for only one, rs2296212 (one-sided allelic P ¼ 0.009) (Supplementary Material, Table S1 ). Subsequent analysis in the replication 2 samples of 1344 Japanese schizophrenic patients and 1344 Japanese control subjects confirmed the association for this SNP (one-sided allelic P ¼ 0.04). The P-value for the association was 5.8 Â 10
25 when the initial genome-wide sample and the total replication 1 þ 2 samples were combined (Table 1) .
Because the SMARCA2 gene encodes BRM in SWI/SNF chromatin remodeling, SNPs within genes that encode proteins potentially involved in chromatin remodeling were re-evaluated for association with schizophrenia. CREBBP, DNMT1, DNMT2, DNMT3A, DNMT3B, HAT1, HDAC2, HDAC3, HDAC4, HDAC7, HDAC9, HNMT3A, MYST1, MYST2, MYST4, SIN3A, SIN3B, SMARCA3, SMARCA4, SMARCA5 and SMARCC1 were selected in addition to the SMARCA2 genes, with a less stringent criteria of association used (P-values of less than 0.05). For this screen, SNPs from the same 100 schizophrenia patients were screened with an Illumina HumanHap370 BeadChip and compared with those in 1868 chromosomes of Japanese volunteers listed in the JSNP database [deposited October 2007, (http:// snp.ims.u-tokyo.ac.jp/index.html)]. Although potentially significant association was observed in the SMARCC1 and DNMT3B genes, this did not exist after correction for multiple testing (Supplementary Material, Table S2 ). An attempt was made to replicate the associations of rs13063042 and rs17079785 in SMARCC1 and rs2424932 in DNMT3B with schizophrenia in the replication 1 sample. However, no significant results were obtained (Supplementary Material, Table S2 ).
The SMARCA2 gene is located at chromosome 9p24.3 and spans 178 282 bp comprising 34 exons. The SNP of rs2296212 was non-synonymous, D1546E, in exon 33. Subsequent genotyping of 34 tag SNPs in the SMARCA2 gene in the replication 1 þ 2 samples identified a significant association with schizophrenia for three SNPs [rs2066111 in intron 12 (allelic P ¼ 8.2 Â 10
25
), rs3763627 in intron 12 (allelic P ¼ 1.2 Â 10
) and rs3793490 in intron 19 (allelic P ¼ 3.0 Â 10 26 ), Fig. 1 and Table 1 ]. Resequencing of the coding region of SMARCA2 in 24 Japanese patients with schizophrenia identified no non-synonymous mutations except for D1546E.
The distance between D1546E and rs3793490 was 95 351 bp and these two SNPs were not in linkage disequilibrium (r 2 ¼ 0,
The three intronic SNPs were in modest linkage disequilibrium with each other; the r squares were 0.59 between rs2066111 and rs3763627, 0.52 between rs206111 and rs3793490 and 0.85 between rs3763627 and rs3793490. Therefore, SNPs in two linkage disequilibrium blocks in the SMARCA2 gene, one in the middle and one in the 3 0 region of the gene, were found to be associated with schizophrenia in our Japanese population. Figure 2 . Alleles observed more frequently in the schizophrenia group were associated with a low expression level of SMARCA2 in the prefrontal cortex. When Australian and Japanese schizophrenic subjects, or schizophrenia patients and controls were separately analyzed, there were no significant differences seen in SMARCA2 expression level. SMARCA2 expression level was not significantly different between the genotypes of rs2066111 and rs2296212.
The risk allele E1546 causes lower nuclear localization efficiency of BRM BRM has several domains highly conserved among species, such as yeast (23), Drosophila (40) and mammals (27) . Although D1546E is located downstream to the bromodomain, the polymorphism is in the highly conserved region among mammalian species, and glutamic acid (E) at the 1546 bp site in human is commonly found among mammalian species (Fig. 3A) . BRM is localized in the nucleus (19) . In order to analyze any functional difference of BRM between the two allele types, localization of BMR was investigated by EGFP fusion protein ( Fig. 3B ) transfected into the human glioblastoma cell line T98G. The D1546 type of EGFP fused BRM (EGFP/BRM Ã D) localized to the nucleus; however, the E1546 type of EGFP fused BRM (EGFP/BRM Ã E) existed both in the cytoplasm and nucleus ( Fig. 3C and D ). Cells transfected with the two different alleles had a different morphology (Fig. 3C ). This finding indicates lower nuclear localization efficiency of the E1546 isoform (BRM Ã E) in transfected cells, and it is hypothesized that the E1546 isoform has less functionality than the D1546 type (BRM Ã D).
Lower function of the E1546 form of BRM was supported by transcriptional changes seen in transfected cells
The functional capability of BRM Ã E was evaluated by comparisons of gene expression changes that were introduced by SMARCA2 Ã E, SMARCA2 Ã D and siRNA targeted towards SMARCA2. pDEST26 expression vectors were constructed with SMARCA2 Ã E or SMARCA2 Ã D and introduced into T98G cells. Transcription of SMARCA2 Ã E and SMARCA2 Ã D was 50-folds higher than that of control cells (Fig. 4A ). The siRNA targeted against the SMRACA2 gene was introduced into the same cell lines and translation level decreased to approximately 1/10 of that from control cells (Fig. 4A ). Transcription levels of SMARCA2 were comparable to the level of translation seen after the immunoblot analysis (Fig. 4A ). After transfection of the pDEST26 with SMARCA2 Ã E, the pDEST26 with SMARCA2
Ã D, and siRNA in T98G cells, gene expression level was measured using Sentrix Human WG-6 BeadChips (Illumina, CA, USA). Expression changes introduced by SMARCA2 Ã E, compared with that of SMARCA2 Ã D, were significantly correlated with those of the siRNA treatment, compared with that of mock-treated cells ( Fig. 4B , P , 0.0001), again supporting a lower functionality of BRM Ã E compared with BRM Ã D. When outliers defined as values exceeding two standard deviations from the mean in SMARCA2 Ã E against SMARCA2
Ã D, and from that in siRNA were excluded, the correlation was more significant (P , 0.00001).
Gene expression changes seen after suppression of SMARCA2 in transfected human cells were correlated with those found in the postmortem prefrontal schizophrenic brains To evaluate the relationship between lower functioning of SMARCA2 and the gene expression profile seen in schizophrenia, gene expression changes after introduction of siRNA to T98G cells were compared with those from the postmortem prefrontal cortex of schizophrenia patients. Data from all frontal cortex studies were utilized to determine the mean expression of each gene. Among 1051 genes with significant expression changes seen in schizophrenic patients from the SMRI database (P , 0.05, SMRIDB, https:// www.stanleygenomics.org/), 445 genes could not be evaluated due to their low expression level in T98G cells. The fold change of expression of the remaining 606 genes from the SMRIDB was significantly correlated with expressional changes seen after siRNA treatment in T98G cells (P , 0.0009) (Fig. 5A ). When outliers defined as mean values exceeding 10-folds in siRNA against mock were excluded, the correlation was still significant (P , 0.003).
Gene expression profiles from Smarca2 knockout mice prefrontal cortex were correlated with those seen in the postmortem prefrontal schizophrenic brains To evaluate the relationship between lower functionality of BRM and the gene expression profile of schizophrenia, gene expression profiles from the prefrontal cortex of Smarca2 knockout mice (41) were compared with those from the postmortem prefrontal cortex of schizophrenic patients in the SMRIDB. Gene expression in the prefrontal cortex of three pairs of Smarca2 2/2 mice and littermate wild-type mice (Smarca2 þ/þ) at 8 weeks of age were measured with MouseWG-6 BeadChips (Illumina, CA, USA). Expression level of 586 genes was significantly different between Smarca2 2/2 mice and Smarca2 þ/þ mice (t-test, P , 0.05). Fifty-two orthologous genes were found between these 586 genes and the 1051 genes with significant expression changes seen from schizophrenic patients compared with controls in the SMRIDB ( Table 2 ). The fold change in expression of these 52 genes in Smarca2 2/2 mice compared with Smarca2 þ/þ mice was significantly correlated with the fold changes of orthologous genes in schizophrenia compared with controls in the SMRIDB (P , 0.002) (Fig. 5B) . When outliers defined as mean values in Smarca2 2/2 mice exceeding 2-folds from the mean in Smarca2 þ/þ mice were excluded, the correlation was more significant (P , 0.001).
Confirmation of genes interacting with BRM by ChIP assay
Although transcriptional changes were observed in many genes by down-or up-regulation of the SMACA2 gene in cultured T98G cells or in the Smarca2 knockout prefrontal brain, they were direct or indirect consequences of interaction with the BRM-containing SWI/SNF chromatin remodeling factors. To confirm the association of endogenous BRM with the promoters of these transcriptionally influenced genes, ChIP assay was carried out using an antibody against BRM. DNA regions that interacted with BRM were collected and the sequence for 21163 to 21026 bp up-stream of the HOMER1 gene confirmed by PCR. The HOMER1 gene was selected because, among the genes in Table 2 , it exhibited a more than 10-fold reduction in the expression in T98G cells after transfection by the siRNA targeted towards SMARCA2, and a more than 10-fold increase after transfection of the pDEST26 with SMARCA2 Ã E or the pDEST26 with SMARCA2 Ã D. These regions were also detected after ChIP assay using an antibody against MeCP2, which interacted with BRM (Fig. 6 ).
Impaired social interaction and prepulse inhibition in Smarca2 knockout mice
To evaluate schizophrenia-related behaviors in Smarca2 knockout mice, social interaction and prepulse inhibition (PPI) of the acoustic startle reflex was measured. Male and female data were combined for the analysis because no sex differences were observed. Smarca2 2/2 mice spent a significantly shorter time when making contact with an unfamiliar intruder mouse compared with mice of the other genotypes ( Fig. 7A , P ¼ 0.03). There was no significant difference in novelty seeking behavior between genotypes (data not shown). Smarca2 2/2 mice showed significant disturbance of PPI at 78 dB (P ¼ 0.02) and a trend toward disturbance of PPI at 82 dB and 86 dB (P ¼ 0.07) compared with the other genotypes (Fig. 7B ).
Smarca2 gene expression in the mouse brains was decreased by psychotogenic drugs treatments and increased by antipsychotic drug treatments
The involvement of aberrant NMDA receptor signaling and a hyperdopaminergic state has been assumed in the pathophysiology of schizophrenia. Smarca2 expression was evaluated in the mouse brain using the MK-801 non-competitive antagonist of NMDA receptors, the indirect dopamine receptor agonist methamphetamine and the antipsychotic drugs haloperidol and olanzapine. The expression of Smarca2 was significantly decreased after the administration of MK-801 or methamphetamine and increased by administration of haloperidol and olanzapine (Fig. 7C) .
DISCUSSION
SNPs in two linkage disequilibrium blocks in the SMARCA2 gene were associated with schizophrenia in Japanese populations and the risk alleles are likely to confer a lower functioning of SMARCA2/BRM through altered gene expression or intracellular localization. Although the study did not find significant differences in SMARCA2 transcription levels in the postmortem prefrontal cortex between schizophrenic patients and controls (data not shown), the SMRI database showed a non-significant trend toward decreased SMARCA2 transcription levels in schizophrenics compared with controls (P ¼ 0.07). Additionally, a disruption of the SMARCA2 gene in a patient with schizophrenia has been reported (42) . BRM is involved in the modification of chromatin structures in epigenetic regulation of gene expression (36) . Therefore, it was hypothesized that low functionality of SMARCA2/BRM is associated with schizophrenia through its pleiotropic effects on transcriptional regulation of many genes. This hypothesis is supported by gene expression profiles from the prefrontal cortex and behavioral observations in Smarca2 knockout mice.
From an evolutionary perspective, the amino acid residue corresponding to human D1546E in SMARCA2 (Smarca2) of dog, mouse, rat, horse, cow and chimpanzee is E. Therefore, E1546 is probably the ancestral type in humans (Fig. 3A) . Because the allele frequencies of D1546 were 0.85 in Japanese, 0.75 in Yoruba and 0.9 in CEPH families (according to the HapMap data), it might be assumed that D1546, the protective allele for schizophrenia, arose during the human evolutionary process and spread due to its positive selection pressure against schizophrenia.
The second finding of the present study is that BRM is a potential key protein in schizophrenia. Functional differences between alleles in humans are likely to be small, as indicated by the relatively small odds ratios of the risk alleles observed in Japanese populations (1.18 to 1.27). Therefore, the contribution of genetic variations in the SMARCA2 gene region to the development of schizophrenia may be small. However, the present study suggests a greater role of the SMARCA2 gene than the genetically determined role in the pathophysiology and amelioration of schizophrenia because psychotogenic drugs (well-established pharmacological models of schizophrenia) decreased Smarca2 expression and an antipsychotic drug increased expression in the mouse brain. These findings support the hypothesis of BRM as being a potential key molecule involved in schizophrenia. The hypothesis is that various psychotogenic factors including genetic ones decrease BRM, which further affects expression of various other genes that then contribute to the development of schizophrenia.
BRM is involved in the epigenetic mechanisms of psychotogenic and antipsychotic drugs. As for the relationship of these drugs with epigenetic mechanisms, the influences of methamphetamine on DNA methyltransferase mRNA levels (43, 44) and that of D2-like antagonists and MK-801 on the phosphorylation of histone H3 at serine 10 and the acetylation of H3-lysine 14 (45) have been reported. The present study also indicates the involvement of the SNF/SWI family protein in the epigenetic mechanisms through which psychotogenic and antipsychotic drugs act.
The statistical evidence in the present study should be considered cautiously given that genotyping was based upon different platforms performed in different laboratories for screening with the Illumina BeadChips. This could likely result in false positives. Therefore, importance was placed on real statistical support from the replication performed. However, the initial screening using 11 883 SNPs and 100 schizophrenia patients is far from a complete genome coverage and has an extremely low power to detect a true association. This may affect the credibility of the results. Confirmation of associations in populations other than Japanese is necessary.
There are many questions yet to be answered. The mechanisms of influences of psychotogenic and antipsychotic drugs on SMARCA2 expression and the mechanisms of regulation of each gene listed in Table 2 involving BRM are unknown. An interaction between the promoter region of the HOMER1 gene and BRM was confirmed using the ChIP assay. HOMER proteins provide constitutive forms of Homer (also known as CC-Homers) and immediate early gene products. Homer proteins interact with both group 1 metabotropic glutamate receptors (mGluRs) of mGluR1 and mGluR5 (46) and Shank-GKAP-PSD95-NMDA receptor complexes, as well as with proteins that regulate intracellular calcium signaling. Homer1 knockout mice also show behavioral and neurochemical phenotypes relevant to schizophrenia (47, 48) .
The finding that psychotogenic drugs decreased Smarca2 expression can be interpreted as suggesting that changes in SMARCA2 are consequences of schizophrenia rather than causes. Although genetic association in humans and altered behavior in Smarca2 knockout mice may support causation at least in part, the experiments from this study indicate the existence of factors that influence SMARCA2 expression and may be related to schizophrenia. Further studies exploring such factors are warranted.
Frequent loss of BRM expression has been reported in lung cancers (49) and gastric cancer (50) and a lower average level of BRM expression in prostate cancers (51) . Controversy concerning the incidence of cancer in schizophrenia exists; however, lower respiratory (52) and prostate cancers (53) in schizophrenia patients have been reported. A recent meta-analysis indicated a slightly increased incidence of lung cancer in schizophrenic patients, but after the data were adjusted for smoking prevalence, this was not seen (54) .
In conclusion, the present study identifies BRM as potentially a key molecule in a wide range of pathophysiology associated with schizophrenia.
MATERIALS AND METHODS

Human subjects
Subjects of schizophrenia for screening, replication 1 and replication 2 were 100 (mean age + SD: 57.5 + 14.9 years, 58 males and 42 females), 576 (mean age + SD: 51.6 + 14.8 years, 322 males and 254 females) and 1344 (mean age + SD: 46.7 + 14.4 years, 733 males and 611 females) and control subjects in replications 1 and 2 were 576 (mean age + SD: 46.8 + 12.5 years, 268 males and 322 females) and 1344 (mean age + SD: 47.8 + 13.8 years, 783 male and 561 female). The replication samples were independent from the sample set used for screening. For every possible paring of individuals, the mean and variance in number of alleles shared identity-by state (IBS) across markers was estimated using the GRR tool (55) . All subjects were of Japanese descent and were recruited from the main island of Japan. All schizophrenic subjects were given a best-estimate lifetime diagnosis according to DSM-IV criteria with obtained consensus from at least two experienced psychiatrists on the basis of all available sources of information, including unstructured interviews, clinical observations and medical records. Control subjects were mentally healthy and had no family history of mental illness within second-degree relatives as selfreported. The study was approved by the Ethics Committees of the University of Tsukuba, Niigata University, Fujita Health University, Nagoya University, Okayama University and Seiwa Hospital, and all participants provided written informed consent.
Postmortem brains
Brain specimens were from European-descent Australian individuals and Japanese individuals. The Australian sample comprised 10 schizophrenic patients and 10 age-and gendermatched controls (56) . The diagnosis of schizophrenia had been made according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria (American Psychiatric Association 1994) by a psychiatrist and a senior psychologist. Control subjects had no known history of psychiatric illness. Tissue blocks were cut from gray matter in an area of the prefrontal cortex referred to as Brodmann's area 9 (BA9). Japanese samples of BA9 gray matter were from 6 schizophrenic patients and 11 age-and gender-matched controls (56) . In addition, postmortem brains of 37 deceased Japanese patients with schizophrenia were also analyzed (56) . The Japanese subjects met the DSM-III-R criteria for schizophrenia. The study was approved by the Ethics Committees of the Central Sydney Area Health Service, University of Sydney, Niigata University, University of Tsukuba, Tokyo Metropolitan Matsuzawa Hospital and the Tokyo Institute of Psychiatry.
Genotyping
Association screening was performed using the Illumina Sentrix Human-1 Genotyping 109 k BeadChip and HumanHap370 BeadChip according to the manufacturer's instructions (Illumina, San Diego CA, USA). All DNA samples were subjected to rigorous quality control to check for fragmentation and amplification. Approximately 750 ng of genomic DNA was used in each sample. Normalized bead intensity data obtained for each sample were entered into the Illumina BeadStudio 3.0 software, which converted fluorescence intensities into SNP genotypes. A GenCall Score of 0.85 was used as a minimum threshold for per-sample genotyping completeness. The mean call rate across all samples was 97.0% for Human-1 and 99.8% for HumanHap370; the call rate was at least 99% for 47021 SNPs for Human-1 and 235868 SNPs for HumanHap370 and at least 95% for 60 568 SNPs for Human-1 and 244 337 for HumanHap370. Concordance rate between Human-1 and HumanHap370 platforms was evaluated by comparisons of genotypes in the 100 screening samples and this gave concordance of over 98.0% for each sample. One thousand one hundred and fifty-two subjects were genotyped twice for each SNP using TaqMan genotyping (Applied Biosystems, Foster City, CA, USA), For a more detailed analysis of the associations of the SMARCA2 gene, the tag SNPs in the gene were selected using the Haploview program (http://www.broad.mit.edu/ mpg/haploview/) with the condition of an r 2 threshold of 0.8 and a minor allele frequency of 0.1, and genotyped by the TaqMan method. Allelic discrimination was performed using the ABI PRISM 7900HT Sequence Detection System using SDS 2.0 software (Applied Biosystems, Foster City, CA, USA).
Cell and animal experiments
Experimental procedures used in cell and animal experiments, including plasmid: construction, knockdown of SMARCA2 by siRNA, cell culture and transfection, RNA and cDNA preparation, northern and western blot analysis, whole-genome expression analysis, real-time PCR, ChIP assay and behavioral pharmacological analyses of mice are described in the Supplementary Material.
Statistical analysis
Initial screening for association with schizophrenia was done for 11 883 SNPs and, in subsequent analysis, 259 SNPs from the HumanHap370 BeadChip and 34 tag SNPs from SMARCA2 were added. Therefore, a P-value corrected by Bonferroni's method for 12 176 pair-wise comparisons, P , 4 Â 10
26
, was considered as significant for overall evidence for association. In this study, genotypic P-values or haplotype P-values were not evaluated to avoid inflation of the P-values due to multiple testing.
In the replication study, 5 SNPs from the initial screening, 3 SNPs from genes related to chromatin remodeling and 34 tag SNPs in the SMARCA2 gene were selected to replicate associations with schizophrenia in the replication samples. A P ¼ 0.05/(5 þ 3 þ 34) , 0.001 was considered as significant in the replication samples. Association and Hardy -Weinberg equilibrium were calculated using chi-test. Haplotype frequencies were estimated using the expectation maximization algorithm. The Haploview program (http://www.broad.mit.edu/ mpg/haploview/) was used to detect the haplotype block.
In real-time PCR experiments, correlation of SMARCA2 gene expression and diagnosis, ethnicity, age, sex, PMI and the pH of brain samples was analyzed by one-way analysis of variance (ANOVA) tests or regression analyses by JMP computer software version 7. In linear multiple regression analysis, genotypes of the SNPs as qualitative variables, age, sex, PMI, pH, diagnosis and ethnicity of brain samples were included as variables. The genotypes of the SNPs were Figure 6 . Chromatin immunoprecipitation (ChIP) assays on DNA harvested from T98G cells. DNA that interacts with SMARCA2 and MeCP2 was evaluated using antibodies against to them. Normal rabbit immunoglobulin G (IgG) was used as negative controls. DNA was detected by PCR using primers for the region 21163 21036 from the HOMER1 exon 1. 1st lane: no template; 2nd lane: DNA template before immunoprecipitation for PCR; 3rd lane: immunoprecipitated DNA template with IgG for negative control. 4th and 5th lanes: immunoprecipitated DNA template with antibodies against SMARCA2 and MeCP2. Figure 7 . Social interaction and PPI in Smarca2 2/2, 2/þ and þ/þ mice and effects of psychotogenic and antipsychotic drugs on Smarca2 gene expression in the mouse brain. (A) The vertical axis is the difference between the time that the test mouse spent sniffing the cylinder where a stimulus mouse was present and the time when stimulus mouse was absent. Genotype was coded as 0, 1 or 2 depending on the number of Smarca2 copies and a simple regression model was fitted (P ¼ 0.03). (B) PPI was recorded for Smarca2 2/2, 2/þ and þ/þ mice using a conditioning, prepulse noise burst of 74, 78, 82 or 86 dB. Smarca2 2/2 mice had impaired PPI in comparison to heterozygous and wild-type litter-mate mice at 78 dB prepulse noise (F-test, P ¼ 0.02), at 82 and 86 dB (P ¼ 0.07). (C) Effects of psychotogenic and antipsychotic drugs on Smarca2 gene expression in the mouse brain. Smarca2 expression levels in the mice brain after treatment with methamphetamine (METH) (n ¼ 5), MK-801 (n ¼ 5) or saline (control) (n ¼ 5) for 12 days (a), haloperidol (HAL) (n ¼ 10), olanzapine (OLZ) (n ¼ 10) or saline (n ¼ 10) for 7 weeks (b). Administration of drugs was by once daily intraperitoneal injection to 4-week-old C57BL/6J male mice. The average relative expression level from the prefrontal cortex, midbrain, hippocampus, thalamus and striatum of the treated group was compared with the saline groups by t-test. assigned to 0, 1 and 2. Differences of SMARCA2 expression levels between genotypes were analyzed by Student's t-tests. A P , 0.05 was considered as significant.
